Head-to-head evidence
Dostarlimab vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline
NCT03739710 · Phase 2 · completed
An open-label platform master study whose posted primary outcome is only the number of participants randomized across sub-studies; no comparative efficacy result for the dostarlimab-containing regimens is reported on the record. With no usable result and no blinding, this is weak evidence.
Next expected readout: November 2026 · NCT05565378 (registry estimate)
Penpulimab
Marketed by Akeso
NCT03866993 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment, with disease progression assessed by an independent radiology committee. Its primary endpoint, progression-free survival, was clearly met, roughly doubling median progression-free survival versus placebo plus chemotherapy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Penpulimab's landscape